Hologic

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products dedicated to serve the healthcare needs of women. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment includes a portfolio of solutions for breast cancer care for radiology, pathology, and surgery. The Diagnostics segment consists of products used to aid in the screening and diagnosis of human diseases. The GYN Surgical segment involves the NovaSure Endometrial Ablation System, the MyoSure Hysteroscopic Tissue Removal System, and the Fluent Fluid Management System. The Skeletal Health segment covers the Horizon DXA and the Fluoroscan Insight FD mini C-arm. The company was founded by S. David Ellenbogen and Jay A. Stein in 1985 and is headquartered in Marlborough, MA.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Hologic exceeds Q1 earnings, eyes growth in women's health

Hologic's Q1 performance surpassed expectations, driven by strong organic growth and strategic initiatives. The company's commitment to women's health, financial strength, and focus on innovation position it well for future growth. Challenges in Breast Health highlight areas for improvement, while opportunities in new markets and products offer avenues for expansion.

Hologic surpasses Q2 expectations, eyes international growth and women's health

Hologic's Q2 performance exceeded expectations, driven by robust organic revenue growth and strong margins across divisions.
While facing challenges like COVID-related revenue declines and seasonal factors, the company's strategic strengths in women's health and international expansion present growth opportunities.
To sustain growth, Hologic must navigate macro uncertainties, balance growth drivers, and capitalize on opportunities in diagnostics and global expansion.
Overall, Hologic's solid financial results, increased revenue guidance, and strategic initiatives position the company for continued success in the healthcare market.

Hologic excels in Q3 earnings, eyes global growth amid challenges

Hologic delivered strong financial results in Q3 2023, driven by robust revenue growth and strategic product offerings across its divisions.
While facing margin challenges and geopolitical uncertainties, the company remains optimistic about sustaining growth and enhancing profitability through operational improvements.
With a focus on innovation, global expansion, and cautious M&A strategies, Hologic is well-positioned to capitalize on opportunities and navigate challenges in the healthcare market.

Hologic surpasses revenue targets, eyes international growth and strategic M&A

Hologic delivered strong financial performance in Q4 2023, exceeding revenue and EPS targets while emphasizing women's health and innovation.
The company's focus on international growth, strategic capital allocation, and product portfolio strength position it well for continued success.
Challenges in regulatory compliance, M&A decisions, and market dynamics require careful navigation for sustained growth.
Opportunities in international expansion, strategic M&A, and product innovation offer avenues for future growth and market leadership.

Hologic surpasses Q1 revenue expectations, eyes international growth opportunities

Hologic delivered strong Q1 2024 results, exceeding revenue guidance and showcasing robust financial performance with organic growth of 5.2% ex-COVID.
The company's focus on innovation, market expansion, and strong customer relationships positions it well for continued growth and success beyond COVID testing.
While facing challenges such as tough comps in Q2 and potential tax rate impacts, Hologic's disciplined growth strategies and commitment to transformative initiatives offer opportunities for future expansion.
With a strong emphasis on AI capabilities, market expansion, and strategic M&A, Hologic is poised for sustained growth and market leadership in the healthcare sector.

Hologic beats Q2 revenue targets, eyes international growth opportunities

Hologic exceeded revenue and EPS expectations in Q2 2024, showcasing growth in key business segments.
While facing challenges in certain revenue streams, the company is focused on international expansion and margin improvement.
Opportunities lie in leveraging international growth, strategic acquisitions, and product utilization trends.
Overall, Hologic's performance reflects resilience post-COVID and strategic focus on innovation and market positioning.

Hologic surpasses Q3 revenue expectations, eyes international growth opportunities

Hologic's Q3 performance reflects resilience and growth across key business segments, supported by strategic investments and operational excellence. With a focus on innovation and international expansion, the company is well-positioned for sustained growth and value creation in the evolving healthcare landscape.

Hologic exceeds Q4 earnings, eyes international growth and new products

Hologic's Q4 2024 earnings call showcased strong performance, strategic strengths, and growth opportunities. Challenges include maintaining margin expansion and balancing international growth. The company's focus on durable revenue base and new product pipeline sets a positive outlook for fiscal 2025.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Hologic, Inc. engages in the development, manufacture, and supply of diagnostics products, medical imaging systems, and surgical products, that focuses on women’s health and well-being through early detection and treatment. It operates through the following segments: Breast Health, Diagnostics, GYN Surgical, and Skeletal Health. The Breast Health segment is involved in a portfolio of solutions for breast cancer care primarily in the areas of radiology, breast surgery, pathology and treatment. The Diagnostics segment offers a range of products, which are used primarily to aid in the screening and diagnosis of human diseases. The GYN Surgical segment is involved in hysteroscopic endometrial ablation systems, tissue removal systems, fluid management systems, and laparoscopic tissue ablation systems and tools. The Skeletal Health segment covers the Horizon DXA and the Fluoroscan Insight FD mini C-arm. The company was founded by S. David Ellenbogen and Jay A. Stein in 1985 and is headquartered in Marlborough, MA.

AGNC Investment

Delta Air Lines

Jabil

Suzano S.A. - ADR

Jabil (JBL), Delta Air (DAL), AGNC Investment (AGNC), Hologic (HOLX) and Suzano (SUZ) are some of the stocks with high ROE to profit from as equity markets start 2023 on a positive note.

5 Stocks With High ROE to Buy as Equity Markets Hold Promise

Hologic was a beneficiary of the pandemic, catching a strong bid across that period. With its FY22 numbers, investors have re-rated the stock back to the upside.

Hologic Deserves To Trade A High Earnings Multiple

Hologic (HOLX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.

Hologic, Inc. (HOLX) Hits Fresh High: Is There Still Room to Run?

Air Products and Chemicals

IDEX

Juniper Networks

MSCI

Five S&P 500 companies are set to beat earnings estimates next week. These are: JNPR, MSCI, IEX, APD and HOLX.

5 S&P 500 Stocks to Buy Ahead of Earnings Next Week

Hologic (HOLX) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Hologic (HOLX) Expected to Beat Earnings Estimates: Should You Buy?

The growing adoption of Panther instruments worldwide will likely drive Hologic's (HOLX) Q1 revenues.

Non-COVID Diagnostics Sales to Aid Hologic (HOLX) Q1 Earnings

For most of the corporate world, Covid-19 was a serious problem.

Hologic Is Coming Off a Covid-19 High; What's Next?

Five Below

Progyny

Impinj

Yum China Hlds

These top-ranked stocks are likely to beat on bottom line in their next releases. Tap Yum China (YUMC), Impinj (PI), Five Below (FIVE), Hologic (HOLX) and Progyny (PGNY).

In Search of an Earnings Beat? Play These Top 5 Stocks

Does Hologic (HOLX) have what it takes to be a top stock pick for momentum investors? Let's find out.

What Makes Hologic (HOLX) a Strong Momentum Stock: Buy Now?

Hologic (HOLX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Why Hologic (HOLX) Could Beat Earnings Estimates Again

Dick's Sporting Goods

PepsiCo

Jabil (JBL), PepsiCo (PEP), DICK'S Sporting (DKS), Hologic (HOLX) and Suzano (SUZ) are some of the stocks with high ROE to profit from as rate hike fears subside.

5 Stocks With High ROE to Buy as Rate Hike Fears Subside

Hologic, Inc. (HOLX) Hit a 52 Week High, Can the Run Continue?

Hologic, Inc. HOLX shares are trading higher today after the company reported preliminary first-quarter revenue results.

What's Going On With Hologic Shares Today? - Hologic (NASDAQ:HOLX)

Hologic, Inc. (NASDAQ:HOLX) has announced preliminary first-quarter revenue that beat recent guidance, sending its shares higher. The innovative medical technology company told investors it expects to report total revenues of approximately $1.1 billion for the three months ended December 31, 2022, a decrease of 27% compared to the prior year period - or 25% in constant currency.

Hologic stock jumps after it announces guidance-beating 1Q revenue

Hologic has managed to achieve impressive financial results in Fiscal Q1 2023.

Hologic's Fiscal Q1 2023 Earnings: A Ray of Hope in a Stormy Year

MARLBOROUGH, Mass.--( BUSINESS WIRE )--Hologic, Inc. (Nasdaq: HOLX) announced today preliminary revenue results for its first fiscal quarter ended December 31, 2022.

Hologic Announces Preliminary Revenue Results for First Quarter of Fiscal 2023

MARLBOROUGH, Mass.--( BUSINESS WIRE )--Hologic, Inc. (Nasdaq: HOLX) announced today that the Company plans to release its financial results for the first quarter of fiscal 2023 on Wednesday, February 1, after the market closes. In conjunction with the release, management will host a conference call that day at 4:30 p.m. Eastern Time.

Hologic to Announce Financial Results for the First Quarter of Fiscal 2023 on Wednesday, February 1, 2023

MARLBOROUGH, Mass.--( BUSINESS WIRE )--Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present at the 41st Annual J.P. Morgan Healthcare Conference on Tuesday, January 10, 2023, at 1:30 p.m. Pacific Time.

Hologic to Webcast Presentation at the 41st Annual J.P. Morgan Healthcare Conference

Hologic (HOLX) registers procedural volumes return in GYN Surgical as well as acceleration from its new business lines.

Hologic's (HOLX) Panther Utilization Rises, Supply Issue Ails

MARLBOROUGH, Mass.--( BUSINESS WIRE )--Hologic, Inc. (Nasdaq: HOLX) announced today that Stacey D. Stewart has been elected to the Company's Board of Directors, effective January 2, 2023. Ms. Stewart was also appointed to the Audit and Finance Committee effective January 2, 2023.

Stacey D. Stewart Elected to Hologic Board of Directors

MARLBOROUGH, Mass.--( BUSINESS WIRE )--Hologic, Inc. (Nasdaq: HOLX) and its subsidiary, Biotheranostics, Inc., today announced new study data showing that the Breast Cancer Index test identified which premenopausal patients with early-stage, hormone-receptor positive (HR+) breast cancer benefited from the addition of ovarian function suppression (OFS) to primary adjuvant endocrine therapy. The Breast Cancer Index test is the first biomarker to be evaluated in a cohort from the landmark Suppression of Ovarian Function Trial (SOFT). The translational study results are featured in the official press program at the 2022 San Antonio Breast Cancer Symposium (SABCS) being held from December 6-10, 2022.1 Full study results were presented during the general session #GS1-06 on December 6 at 3:15 p.m. CST.

New Data Presented at SABCS 2022 Reveal Expanded Predictive Value of the Breast Cancer Index™ Test for Ovarian Function Suppression in Premenopausal Women with HR+ Breast Cancer

Investors continue to be optimistic about Hologic (HOLX) on the back of its continued strength in the Breast Health arm.

Here's Why You Should Retain Hologic (HOLX) Stock For Now

MARLBOROUGH, Mass.--( BUSINESS WIRE )--Hologic, Inc. (Nasdaq: HOLX), an innovative medical technology company primarily focused on improving women's health, swept the 2022 IMV ServiceTrak™ Awards for Mammography, taking home awards for Best Service, Best Customer Satisfaction and Best System Performance. This is the 10th consecutive year that Hologic has ranked first in the industry for Mammography System Performance and Customer Satisfaction and the eighth year for Mammography Service.

Hologic Ranked #1 for Mammography System Performance and Customer Satisfaction for 10th Consecutive Year

MARLBOROUGH, Mass.--( BUSINESS WIRE )--Hologic, Inc. (Nasdaq: HOLX) will exhibit its extensive portfolio of breast and skeletal health products at the 108th Scientific Assembly and Annual Meeting of the Radiological Society of North America (RSNA) from Nov. 27 to Dec. 1. Among the full suite of breast biopsy and surgery solutions will be Hologic's Affirm ® Contrast Biopsy software, which will be on display for the first time since becoming commercially available in the United States.

Hologic to Showcase Portfolio of Comprehensive Breast and Skeletal Health Solutions at RSNA 2022

MARLBOROUGH, Mass.--( BUSINESS WIRE )--Hologic, Inc. (Nasdaq: HOLX) announced today that the Company will present virtually at the 5th Annual Evercore ISI HealthCONx Conference on Tuesday, November 29, 2022, at 2:40 p.m. Eastern Time.

News for Hologic Stock (HOLX)